CJC-1295.

What sellers claim

CJC-1295 is often grouped with growth-hormone secretagogues and advertised for fat loss, muscle, recovery or sleep. Those are claims about outcomes. They require controlled human evidence with a defined product and comparator, not a receptor diagram or a testimonial. See storage claims, product quality and travel for practical context. Explore how trials compare treatments.

For tested sport, check peptides and anti-doping rules. Compare the distinct studies in CJC-1295 versus ipamorelin.

For the bigger picture, follow the growth-hormone signal and its connection to muscle, fat and sleep.

For the related family, compare sermorelin, tesamorelin and CJC-1295 or start with the sermorelin profile.2

What did the human hormone studies show?

A 2006 paper reported two randomised, double-blind, placebo-controlled studies in healthy adults, lasting 28 and 49 days. Researchers studied a long-acting CJC-1295 preparation and measured growth hormone and IGF-1, a growth-related signalling protein. The preparation was administered by injection under the skin in both studies. The findings do not establish the effects or safety of other routes.

The measurements increased after administration. Those are biological signals, not proof of better sleep, recovery, muscle function or long-term health. The short studies also cannot establish long-term safety or show that a differently formulated online product has the same effects. The paper reports 42 participants in the single-dose study and 24 in the multiple-dose study. ConjuChem, the product developer, supported the work.4

What adverse events did those studies report?

In the single-dose study, 33 of 35 participants receiving CJC-1295 and 2 of 7 receiving placebo reported at least one adverse event; the paper described those events as mild or moderate. Injection-site reactions were common, while headache, diarrhoea and flushing or other vasodilatory reactions were also reported. No serious adverse reactions were reported in either of the two studies. These small, short studies cannot establish long-term safety or a reliable rate for online products. Separately, the FDA identifies serious adverse events associated with CJC-1295 in its compounding assessment; those reports are not an incidence estimate.

A separate phase 2 study in people with HIV and increased abdominal fat was terminated. In its 2024 briefing, FDA described reports that a participant died after an acute heart attack and that the attending physician considered coronary artery disease the most likely explanation; the briefing said the trial data were not published. This does not establish whether CJC-1295 contributed to the death or how often a serious event might occur. The ClinicalTrials.gov record, last updated in 2006, listed the study as terminated and had no results posted when checked on 6 November 2026. Absence of results in that record does not prove they were never published elsewhere.4126

What regulators can actually say

FDA’s advisory materials say the available literature is too limited to understand the historical use of all CJC-1295 forms in compounded products. The agency identifies immunogenicity and characterisation concerns and reports serious events including increased heart rate and systemic vasodilatory reaction. This is a safety signal, not an estimate of incidence.

FDA also identified nonclinical safety signals for CJC-1295 with DAC, including injection-site injury in animal studies and signs of genetic damage in pituitary-cell experiments. Some animal toxicity studies were available only as abstracts. FDA found no long-term carcinogenicity studies and could not rule out pituitary overgrowth or tumours with prolonged exposure. These findings and uncertainties do not establish that CJC-1295 causes cancer in people or predict an individual’s risk.12

Why the form matters

Names can obscure real differences. FDA materials distinguish CJC-1295 substances with a drug affinity complex (DAC) from forms without it; the added group changes the molecule. Sellers may use “CJC-1295”, “no DAC” or “modified GRF” inconsistently, so a name alone cannot establish which substance is in a vial. The long-acting preparation in the hormone studies cannot automatically stand in for a different substance or commercial formulation. Salt, concentration, route and manufacturing also matter. A “research use only” label does not establish sterility, identity, dose accuracy or clinical effectiveness. This profile does not provide a sourcing or injection guide. Understand CJC-1295 with DAC, no DAC and the human studies.253

Development & regulatory context

These selected records are not a complete global legal-status list. Approval depends on the product, use, population and country; check each record’s date.